9 completed, 3 terminated, 2 active not recruiting, 1 not yet recruiting. 18 Phase 2, 4 Phase 1, 2 Phase 3.
Follow HER-2 Positive Breast Cancer: new trials by email Literature Review of HER-2 Positive Breast Cancer trials Research Report on HER-2 Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) Lipo-Dox®, Cyclophosphamide, Trastuzumab (Herceptin) - HER-2 Positive Breast Cancer | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 54 | 2026-04-30 | 2026-05-04 |
| Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy - Breast Cancer - Infiltrating Ductal Carcinoma, HER-2 Positive Breast Cancer | Phase 2 | Recruiting | Legacy Health System | 30 | 2026-04-27 | 2026-05-01 |
| A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Abemaciclib, Trastuzumab, Fulvestrant - Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Eli Lilly and Company | 237 | 2016-05-23 | 2024-11-26 |
| Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer nab-paclitaxel, Trastuzumab - Breast Cancer, Estrogen Receptor Negative Neoplasm | Phase 2 | Terminated | Osaka Medical College | 30 | 2015-11-01 | 2019-08-28 |
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA T-DM1, Pertuzumab, Excision of tumor/mastectomy - HER-2 Positive Breast Cancer, Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 164 | 2015-01-01 | 2026-10-02 |
| A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer Liposomal doxorubicin, Docetaxel, Trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 49 | 2014-12-17 | 2025-02-03 |
| Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer docetaxel + trastuzumab sc + pertuzumab, trastuzumab emtansin - Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Thomas Hatschek | 202 | 2014-11-01 | 2020-08-13 |
| Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Ruxolitinib, Trastuzumab - Metastatic Breast Cancer, Breast Carcinoma | Phase 1 / Phase 2 | Completed | Dawn L. Hershman | 32 | 2014-06-01 | 2023-08-24 |
| Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Tesevatinib, Trastuzumab - HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | Phase 1 / Phase 2 | Terminated | Kadmon Corporation, LLC | 17 | 2014-05-01 | 2022-04-27 |
| An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer ganetespib - Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 51 | 2012-07-01 | 2015-11-05 |
| HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 T-DM1, 89Zr-trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | Jules Bordet Institute | 90 | 2012-05-01 | 2025-03-31 |
| A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Everolimus, Vinorelbine, Trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 32 | 2011-09-01 | 2018-12-17 |
| Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Nab-paclitaxel - Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Osaka Medical College | 46 | 2011-09-01 | 2015-04-22 |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Carboplatin, background treatment - Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II | Phase 2 / Phase 3 | Completed | GBG Forschungs GmbH | 595 | 2011-08-01 | 2016-02-15 |
| Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer eribulin, carboplatin, trastuzumab - HER-2 Positive Breast Cancer | Phase 1 / Phase 2 | Terminated | Vector Oncology | 12 | 2011-08-01 | 2015-08-28 |
| Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer Trastuzumab, Paclitaxel, Epirubicin - HER-2 Positive Breast Cancer | Phase 2 | Unknown | Zhimin Shao | 100 | 2011-08-01 | 2012-08-23 |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer AUY922 - Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Texas Tech University Health Sciences Center, El Paso | 2011-07-01 | 2017-05-09 | |
| Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer Trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | Lucia Del Mastro,MD | 43 | 2011-03-01 | 2024-05-09 |
Breast Neoplasms (11) · Brain Neoplasms (2) · Carcinoma, Ductal, Breast (1) · Inflammatory Breast Neoplasms (1) · Pathologic Complete Response (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (13) · Neoplasms by Site (13) · Breast Diseases (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Ductal (1) · Disease Attributes (1)
Trastuzumab (10) · Ado-Trastuzumab Emtansine (3) · Carboplatin (3) · pertuzumab (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Docetaxel (2) · Doxorubicin (2) · Paclitaxel (2) · 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (1) · Bevacizumab (1) · Cyclophosphamide (1) · Epirubicin (1) · Everolimus (1) · Fulvestrant (1)
Osaka Medical College (2) · Dana-Farber Cancer Institute (1) · Dawn L. Hershman (1) · Eli Lilly and Company (1) · GBG Forschungs GmbH (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Jules Bordet Institute (1) · Kadmon Corporation, LLC (1) · Legacy Health System (1) · Lucia Del Mastro,MD (1) · National Taiwan University Hospital (1) · Synta Pharmaceuticals Corp. (1) · Texas Tech University Health Sciences Center, El Paso (1) · Thomas Hatschek (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (8) · Belgium (3) · Italy (3) · Argentina (2) · Brazil (2) · Germany (2) · Japan (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Australia (1) · Canada (1) · China (1) · France (1) · Greece (1)
Mitsuhiko Iwamoto, MD, PhD (2) · Adrienne Waks, MD (1) · Anna Fedeli, MD (1) · Carey K Anders, MD (1) · Dawn Hershman, MD, MS (1) · Gunter von Minckwitz, MD, Prof (1) · Jonas Bergh, Professor (1) · Lee Schwartzberg, MD, FACP (1) · Lucia Del Mastro, MD (1) · Patrick Flamen, MD/PhD (1) · Thomas Hatschek, Assoc prof (1) · Zeina Nahleh, M.D. (1) · Zhi-Ming Shao, MD (1)
PMID 24794243, PMID 25199759, PMID 25534375, PMID 25579459, PMID 26598545, PMID 28715532, PMID 29938395, PMID 30963212, PMID 32353342, PMID 34165503, PMID 36449695, PMID 37906649, PMID 38175448, PMID 38300710, PMID 41543393
2015 (1), U01CA168426 (1)